中银港股通医药混合

Search documents
今年以来“翻倍基”数量达16只
Zheng Quan Ri Bao· 2025-08-15 17:15
本报记者 方凌晨 汇添富香港优势精选混合(QDII)A以143.24%的年内净值增长率暂居榜首。从最新披露情况来看,该基金在今年二季度 对组合的重仓方向、结构、个股调整不多,仍继续看好创新药方向。截至今年二季度末,汇添富香港优势精选混合(QDII)股 票投资仓位达92.65%,其重仓股包括等。 此外,除了长城医药产业精选混合发起式、中银港股通医药混合发起等医药主题基金,诺安精选价值混合、中航优选领航 混合发起、嘉实互融精选股票等"翻倍基"也选择重仓创新药。诺安精选价值混合基金管理人表示,今年二季度创新药板块主要 演绎了"大额对外授权预期"这一逻辑,符合该基金"寻找与时代相契合的超级大单品"的选股策略。 亮眼的业绩表现也吸引了市场资金持续流入,部分"翻倍基"规模增长显著。截至8月14日,广发中证香港创新药(QDII- ETF)、汇添富国证港股通创新药ETF的上市基金规模已达190.43亿元、149.94亿元。为了保证基金的稳定运作和保护基金份额 持有人的利益,部分基金则已选择限购。例如汇添富香港优势精选混合(QDII)已在7月份下旬暂停申购。 汇添富香港优势精选混合(QDII)基金经理张韡认为,目前市场对创新药 ...
超300只主动权益类基金净值创年内新高
Shang Hai Zheng Quan Bao· 2025-04-29 20:02
Group 1 - Over 300 active equity funds have reached new year-to-date highs in net value since April 7, driven by structural investment opportunities and a focus on domestic consumption [1][2] - As of April 28, 38 funds achieved new year-to-date highs, with a total of 302 funds since April 7, reflecting a market rebound supported by favorable policies [1][2] - Funds heavily invested in the consumer sector, such as Guotai Consumer Select and Pengyang Consumer Industry Mixed Fund, have shown remarkable performance amid rising domestic demand [1] Group 2 - The Shunwan Lingxin LeRong One-Year Holding Mixed Fund has reported over 30% returns year-to-date, focusing on trendy toys, gold jewelry, and pet-related sectors [2] - The Longcheng Pharmaceutical Industry Selected Mixed Fund has achieved a year-to-date return of 49.78%, with several other pharmaceutical funds also exceeding 35% returns [2] - Fund managers are increasingly adapting their strategies to capture emerging consumption opportunities, moving away from traditional investment paths [3] Group 3 - Fund managers emphasize the importance of understanding consumer demands and adapting to the preferences of younger generations, which is driving a new consumption cycle [3] - Investment strategies are evolving to include a broader range of assets and sectors, focusing on growth stocks, policy-driven companies, and dividend-paying value companies [3]